Acadia pharmaceuticals inc. ACAD.US AI Analysis
BetaUS StockHealthcare
(No presentation for ACAD)
ACAD Value Score
3
24
15
Average Growth
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ACAD Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
Entry
Exit
The Backtest Result of ACAD from 2007-01-01 till Now
- -11.81%
- Cumulative Return
- -0.68%
- Annual Return
- 29.72%
- Volatility
- -0.02
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to June, 2025. (Total Trades: 3)
| ACAD | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | 67% | 47% | 55% |
| Avg Return | 8.3% | 46.4% | 58.3% |
| Avg Profit | 42.9% | 145.8% | 131.3% |
| Avg Loss | -60.8% | -40.5% | -31% |
| Avg Risk-Reward Ratio | 70.6% | 360% | 423.5% |